CureVac N.V. Form 6-K (Jan. 28, 2021)
Summary
A Form 6-K Report of Foreign Private Issuer furnished by CureVac N.V., Commission File Number 001-39446, for the month of January 2021. Its exhibit index lists Exhibit 99.1, a press release dated January 28, 2021 announcing the pricing of a $450 million follow-on public offering of common shares. The cover page records that the registrant files annual reports under cover of Form 20-F. It is signed /s/ by Franz-Werner Haas, Chief Executive Officer, and dated January 28, 2021.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“CureVac N.V. Form 6-K (Jan. 28, 2021).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2021-01-28-0001104659-21-008389-b49ed261cb/
, SHA-256 9f96a6ec129967004f8a481172fa6afa4ce60ff3a3c7f5e56632725fbb11d061.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission File Number 001-39446 CureVac N.V. Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: FORM 20-F x FORM 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: YES ¨ NO x If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______ SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: January 28, 2021 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | Press Release dated January 28, 2021 – CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares
File and source
- File
- SEC_CVAC_6-K_filed2021-01-28_0001104659-21-008389.htm
- Size
- 10,795 bytes
- SHA-256
- 9f96a6ec129967004f8a481172fa6afa4ce60ff3a3c7f5e56632725fbb11d061
- Original
- www.sec.gov